ORLANDO, FL, USA (UroToday.com) - It has long been known that androgens (testosterone and dihydrotestosterone) fuel tumor growth in prostate cancer, and therapies that reduce circulating levels are the standard of care in early-stage disease (e.g., leuprolide).
Ketoconazole, an antifungal agent, has been used off-label to treat prostate cancer because of its inhibition of CYP17 lyase. Recently, drug developers have targeted CYP17 inhibition to reduce the biosynthesis of androgens, and one, abiraterone acetate, is approved in combination with prednisone for treating castration resistant prostate cancer (CRPC)....Click here to enlarge and view the poster
Presented by Douglas Burtner Jacoby and Martin Williams at the 2013 Genitourinary Cancers Symposium - February 14 - 16, 2013 - Rosen Shingle Creek - Orlando, Florida USA
Tokai Pharmaceuticals, Cambridge, MA
View Full 2013 GU Cancers Symposium Coverage
